Granite Point Capital Management’s DiaMedica Therapeutics DMAC Stock Holding History

Granite Point Capital Management’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-184,380	Closed	-$1.69M	–	167
2021 Q1	$1.69M	Sell	184,380 -362,475	-66%	-$3.39M	0.06%	103
2020 Q4	$5.54M	Sell	546,855 -100,000	-15%	-$547K	0.28%	33
2020 Q3	$2.74M	Buy	646,855 +169,625	+36%	+$897K	0.15%	75
2020 Q2	$3.31M	Hold	477,230	–	–	0.17%	62
2020 Q1	$1.34M	Buy	477,230 +250,000	+110%	+$1.03M	0.75%	39
2019 Q4	$1.1M	Hold	227,230	–	–	0.17%	52
2019 Q3	$470K	Sell	227,230 -2,740	-1%	-$8.86K	0.07%	58
2019 Q2	$1.14M	Buy	+229,970	New	+$795K	0.08%	57

Other funds holding DMAC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MHP

Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

JAMONY

Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return

Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Granite Point Capital Management's DMAC Position: Q2 2021 in Review

Granite Point Capital Management sold out of DiaMedica Therapeutics (DMAC) in Q2 2021, closing a stake of 184,380 shares — an estimated $1.69M sold.

Granite Point Capital Management first reported a position in DMAC in Q2 2019 and held it in 8 quarters. The position peaked at $5.54M in Q4 2020. 43 funds tracked by Wall St. Rank hold DMAC as of Q2 2021.

Granite Point Capital Management reported no remaining DiaMedica Therapeutics position as of Q2 2021 after selling out during the quarter.
Granite Point Capital Management sold 184,380 DiaMedica Therapeutics shares in Q2 2021, an estimated $1.69M.
Granite Point Capital Management first reported a position in DiaMedica Therapeutics in Q2 2019 and held it in 8 quarters.
Granite Point Capital Management's DiaMedica Therapeutics position peaked at $5.54M in Q4 2020.
43 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2021.

Based on Granite Point Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.